On 15 October 2026, a group of 47 Democratic US senators, led by Sen. Patty Murray of Washington, sent a six-page letter to EPA Administrator Lee Zeldin opposing a federal plan to test wastewater for residues of abortion medication Jezebel. The protest targets an EPA investigation announced in September that would pull water samples from metropolitan areas and screen them for mifepristone and misoprostol, the drugs used in medication abortion.
Key takeaways
- Forty-seven Democratic senators, led by Sen. Patty Murray (D-Wash.), wrote a six-page letter challenging the EPA's wastewater surveillance plan Jezebel.
- The EPA launched a formal investigation in September to test water samples from "different metropolitan areas" for mifepristone and misoprostol Jezebel.
- EPA researchers told the Trump administration in 2025 it was technically possible to trace wastewater for abortion medication Jezebel.
- Dozens of Republican legislators asked Administrator Lee Zeldin in June whether the EPA had "existing EPA-approved methods for detecting mifepristone" in water supplies Jezebel.
- Zeldin said in May 2026 he was not "aware" of the EPA's plans to surveil wastewater, a claim the senators also challenged Jezebel.
What happened
The letter argues that using the Safe Drinking Water Act (SDWA), a 1974 law originally written to enforce basic public health standards for the country's water supply, as a vehicle to hunt for pharmaceuticals is a misuse of the statute Jezebel. The senators wrote: "It is deeply alarming that this kind of radical, anti-science campaign might have an audience at the EPA. While there is no scientific evidence that would support mifepristone and misoprostol as candidates for surveillance by the EPA, there has been a targeted political pressure campaign by anti-abortion activists to urge the agency to use the Safe Drinking Water Act (SDWA)." Jezebel
According to the report, Zeldin framed his decision as an effort to identify "potential unknown pollutants" in drinking water, even as the agency this year "gutted" the SDWA Jezebel. The senators added that "this study is a departure from the EPA's historic role in protecting our water and air from actual threats to human health and the environment" Jezebel.
The same report notes that earlier state-level activity, including an April 2025 Texas state bill proposed by state Sen. Bryan Hughes (R), had already pushed for wastewater treatment plants to test for abortion pills and contraceptive hormones Jezebel. The senators' letter is the most visible federal-level pushback so far, but the source does not report whether the EPA has responded, whether sampling has begun, or when any results will be published.
Specification read
For a water-quality buyer, this event is not a procurement, an upgrade, or a permit award. The source does not report a plant flow rate, a sample volume, a contract value, a laboratory capacity, or a treatment train, so the scale of the EPA program in m³/day, MLD, or population equivalent cannot be calculated from the supplied text. What the source does say is that the program is framed as a targeted survey for two specific pharmaceutical residues in metropolitan-area water, run under the statutory umbrella of the Safe Drinking Water Act, and that a formal EPA investigation is already underway Jezebel. For a utility or industrial buyer, the operational consequence is not a new treatment stage but a new analytical question layered onto existing influent and effluent monitoring: whether a plant's already-deployed screening, biological, and tertiary trains are being asked to generate samples for a federal pharmacovigilance program rather than for routine NPDES or SDWA compliance. If your site already runs an advanced treatment train with on-site or contract lab capacity for trace organics, this story is mainly a regulatory-watch item: a new federal sampling request may arrive at your influent, and your procurement team should be ready to scope whether the existing Best Technology to Remove COD BOD From Industrial Wastewater (2026 Buyer Guide) and PFAS Removal Methods Comparison 2026: Industrial Options Tested monitoring chain can absorb the workload before new contracts are signed.
FAQ
What is the EPA actually planning to test for?
The agency has launched a formal investigation to collect water samples from "different metropolitan areas" and test them for mifepristone and misoprostol, the two drugs used in medication abortion Jezebel. The source does not report which laboratories will run the assays or at what detection limit.
Has any sampling actually started?
The source does not report a start date, a sample volume, or a list of participating utilities. It confirms only that a formal investigation was launched in September and that the senators' letter was sent on 15 October 2026 Jezebel.
Does this change the treatment train my plant has to install?
No. The source describes a surveillance and sampling program, not a new discharge limit, so no retrofit of biological, tertiary, or disinfection stages is implied by the article Jezebel. Operators should expect a possible new sampling request, not a new treatment obligation.
What should a procurement lead do now?
The source does not report a contract value, a supplier shortlist, or a bid window, so cost and lead time cannot be quoted from the supplied text Jezebel. The reasonable next step is to track whether the EPA responds to the 15 October 2026 letter and whether a federal sampling protocol is published.
